Chris Hughes, Columnist

All of Monsanto's Problems Just Landed on Bayer

Shareholders are taking fright over a case linking Roundup weed killer to cancer.

August 13, 2018 at 11:45 AM UTC

Chris Hughes is a Bloomberg Opinion columnist covering deals. Previously, he worked for Reuters Breakingviews, the Financial Times and the Independent newspaper.

Bottles of Roundup weed killer move along the production line.
Photographer: Jasper Juinen

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

The true price of Bayer AG's purchase of Monsanto Co. is suddenly in doubt after the U.S. crop science behemoth lost a court case over claims its Roundup weed killer causes cancer.

The verdict wiped 12 billion euros ($14 billion) off the German drugmaker's market value on Monday – about 20 percent of the total value of the acquisition.